NO20013469L - Fremgangsmåter for glukagonsuppresjon - Google Patents
Fremgangsmåter for glukagonsuppresjonInfo
- Publication number
- NO20013469L NO20013469L NO20013469A NO20013469A NO20013469L NO 20013469 L NO20013469 L NO 20013469L NO 20013469 A NO20013469 A NO 20013469A NO 20013469 A NO20013469 A NO 20013469A NO 20013469 L NO20013469 L NO 20013469L
- Authority
- NO
- Norway
- Prior art keywords
- procedures
- glucagon suppression
- exendin
- glucagon
- suppression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11638099P | 1999-01-14 | 1999-01-14 | |
US13201799P | 1999-04-30 | 1999-04-30 | |
US17536500P | 2000-01-10 | 2000-01-10 | |
PCT/US2000/000942 WO2000041548A2 (en) | 1999-01-14 | 2000-01-14 | Methods for glucagon suppression |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20013469D0 NO20013469D0 (no) | 2001-07-12 |
NO20013469L true NO20013469L (no) | 2001-09-14 |
NO328077B1 NO328077B1 (no) | 2009-11-23 |
Family
ID=27381821
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20013469A NO328077B1 (no) | 1999-01-14 | 2001-07-12 | Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering. |
NO2010010C NO2010010I1 (no) | 1999-01-14 | 2010-05-11 | Exendin-4 (Exenatid) |
NO2010012C NO2010012I1 (no) | 1999-01-14 | 2010-05-20 | Exennatid (Eksenatid) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2010010C NO2010010I1 (no) | 1999-01-14 | 2010-05-11 | Exendin-4 (Exenatid) |
NO2010012C NO2010012I1 (no) | 1999-01-14 | 2010-05-20 | Exennatid (Eksenatid) |
Country Status (18)
Country | Link |
---|---|
US (3) | US6872700B1 (no) |
EP (2) | EP1658856B1 (no) |
JP (1) | JP2002538084A (no) |
KR (2) | KR20070051948A (no) |
CN (1) | CN100425284C (no) |
AT (2) | ATE460942T1 (no) |
AU (2) | AU770712B2 (no) |
BR (1) | BRPI0007823A8 (no) |
CA (1) | CA2356331C (no) |
CY (1) | CY1106347T1 (no) |
DE (2) | DE60032331T2 (no) |
DK (1) | DK1143989T3 (no) |
ES (2) | ES2343072T3 (no) |
HK (1) | HK1046105A1 (no) |
NO (3) | NO328077B1 (no) |
NZ (1) | NZ512657A (no) |
PT (1) | PT1143989E (no) |
WO (1) | WO2000041548A2 (no) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE493998T1 (de) | 1996-08-08 | 2011-01-15 | Amylin Pharmaceuticals Inc | Pharmazeutische zusammensetzung mit einem exendin-4-peptid |
KR100637433B1 (ko) * | 2004-05-24 | 2006-10-20 | 삼성에스디아이 주식회사 | 발광 표시 장치 |
US6703359B1 (en) * | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
DE60032331T2 (de) | 1999-01-14 | 2007-06-21 | Amylin Pharmaceuticals, Inc., San Diego | Exendine zur glucagon suppression |
US6444788B1 (en) | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US6569832B1 (en) * | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
AU2014277804B2 (en) * | 2001-07-31 | 2016-12-01 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1 exendin-4 peptide analogs and uses thereof |
YU31004A (sh) * | 2001-10-18 | 2006-08-17 | Bristol-Myers Squibb Company | Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja |
CA2501677A1 (en) * | 2002-10-22 | 2004-05-06 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
WO2004050115A2 (en) * | 2002-12-03 | 2004-06-17 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
SI1605897T1 (sl) * | 2003-03-19 | 2012-11-30 | Lilly Co Eli | Polietilen glikol povezane GLP spojine |
CA2554458A1 (en) * | 2004-01-30 | 2005-08-11 | Waratah Pharmaceuticals, Inc. | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
PT2100904E (pt) | 2004-04-23 | 2010-09-24 | Conjuchem Biotechnologies Inc | Fase sólida para utilização num método para a purificação de conjugados de albumina |
BRPI0512988A (pt) | 2004-07-08 | 2008-04-22 | Novo Nordisk As | método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica |
EP1841448A2 (en) * | 2004-12-30 | 2007-10-10 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring beta-cell mass and function |
US8716221B2 (en) * | 2005-01-14 | 2014-05-06 | Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. | Modified exendins and uses thereof |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
EP1888043A4 (en) * | 2005-03-11 | 2010-07-28 | Endo Pharmaceuticals Solutions | OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE |
CA2619426C (en) | 2005-08-19 | 2016-06-21 | Amylin Pharmaceuticals, Inc. | Exendin for treating diabetes and reducing body weight |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
JP5096363B2 (ja) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Glp−1のポリマ複合体 |
US20070269863A1 (en) * | 2005-12-22 | 2007-11-22 | Bridon Dominique P | Process for the production of preformed conjugates of albumin and a therapeutic agent |
AU2007266475B2 (en) | 2006-05-30 | 2009-12-03 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
DK2049081T3 (da) | 2006-08-09 | 2013-02-25 | Intarcia Therapeutics Inc | Osmotiske leveringssystemer og stempelarrangementer |
CN102827284B (zh) * | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
KR100805208B1 (ko) | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
PT2157967E (pt) * | 2007-04-23 | 2013-04-03 | Intarcia Therapeutics Inc | Formulações de suspensões de péptidos insulinotrópicos e suas utilizações |
WO2009046859A2 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of af12198 and dago as therapeutic agents |
JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
WO2009143285A2 (en) | 2008-05-21 | 2009-11-26 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholestrol and triglycerides |
JP5622725B2 (ja) * | 2008-06-25 | 2014-11-12 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド.Endo Pharmaceuticals Solutionsinc. | エキセナチド及び他のポリペプチド類の持続的送達 |
AU2009262263B2 (en) * | 2008-06-25 | 2014-08-14 | Endo Pharmaceuticals Solutions Inc. | Octreotide implant having a release agent |
CN104248623B (zh) | 2008-09-04 | 2020-04-03 | 安米林药品有限责任公司 | 使用非水性载体的持续释放制剂 |
CN101870728A (zh) | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
EP2435061A4 (en) | 2009-05-28 | 2013-03-27 | Amylin Pharmaceuticals Inc | DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS |
KR101112578B1 (ko) * | 2009-07-16 | 2012-02-16 | 성균관대학교산학협력단 | 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법 |
CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
KR102148624B1 (ko) | 2009-09-28 | 2020-08-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
MX2012005912A (es) | 2009-11-23 | 2012-10-05 | Amylin Pharmaceuticals Inc | Conjugado de polipeptido. |
CN102770152B (zh) | 2009-11-25 | 2016-07-06 | 阿瑞斯根股份有限公司 | 肽类的粘膜递送 |
NZ603169A (en) | 2010-04-27 | 2015-02-27 | Zealand Pharma As | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
MX345245B (es) | 2010-09-28 | 2017-01-23 | Amylin Pharmaceuticals Llc | Polipeptidos manipulados que tienen duracion de accion incrementada. |
DK3241558T3 (da) | 2010-09-28 | 2021-04-26 | Aegerion Pharmaceuticals Inc | Højopløselige leptiner |
WO2012088157A2 (en) | 2010-12-22 | 2012-06-28 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonists for islet cell transplantation |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012162547A2 (en) | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
KR101357117B1 (ko) * | 2011-06-28 | 2014-02-06 | 비앤엘델리팜 주식회사 | 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 |
JP6040464B2 (ja) | 2011-07-08 | 2016-12-07 | アエゲリオン・ファーマシューティカルズ・インコーポレイテッドAegerion Pharmaceuticals, Inc. | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
WO2013009545A1 (en) | 2011-07-08 | 2013-01-17 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
CN104144704B (zh) | 2011-11-03 | 2018-03-23 | 西兰制药公司 | Glp‑1受体激动剂肽胃泌素缀合物 |
CN104302772B (zh) | 2012-05-18 | 2017-11-10 | 爱德迪安(北京)生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
EP2863954A1 (en) | 2012-06-21 | 2015-04-29 | Indiana University Research and Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
MX356957B (es) | 2012-07-23 | 2018-06-20 | Zealand Pharma As | Analogos del glucagon. |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
SG11201602965WA (en) | 2013-10-17 | 2016-05-30 | Zealand Pharma As | Acylated glucagon analogues |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
US10626156B2 (en) | 2013-12-06 | 2020-04-21 | Jie Han | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
EP3082847A1 (en) | 2013-12-20 | 2016-10-26 | Indiana University Research and Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
RU2573933C1 (ru) * | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
CN107636010B (zh) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | 酰化胰高血糖素类似物 |
BR112017024997A2 (pt) | 2015-05-22 | 2018-07-31 | The Bot Of The Leland Stanford Junior University | tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1 |
KR101661332B1 (ko) | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 |
KR20240042548A (ko) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
CR20180378A (es) | 2015-12-23 | 2018-12-06 | Amgen Inc | Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1 |
US11123405B2 (en) | 2015-12-23 | 2021-09-21 | The Johns Hopkins University | Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions |
US10653753B2 (en) | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
BR112018068639A2 (pt) * | 2016-03-16 | 2019-07-30 | Prolynx Llc | conjugados de liberação estendida de análogos de exenatida |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
EP3515408A1 (en) | 2016-09-23 | 2019-07-31 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
US11020484B2 (en) | 2016-11-21 | 2021-06-01 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
CN117384274A (zh) | 2016-12-09 | 2024-01-12 | 西兰制药公司 | 酰化的glp-1/glp-2双重激动剂 |
RU2019122785A (ru) * | 2016-12-22 | 2021-01-22 | Санофи | Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
KR20200019122A (ko) | 2017-06-20 | 2020-02-21 | 암젠 인크 | Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법 |
AU2020233876A1 (en) | 2019-03-08 | 2021-09-23 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
CN110151980B (zh) * | 2019-06-30 | 2022-12-09 | 中国药科大学 | Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用 |
WO2022266467A2 (en) | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Recombinant histone polypeptide and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
US5452284A (en) * | 1992-09-14 | 1995-09-19 | Matsushita Electric Industrial Co., Ltd. | Optical recording/reproducing medium and apparatus using land and groove encoded information signals and identification signals including position information |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
CZ69596A3 (en) | 1993-09-07 | 1997-06-11 | Amylin Pharmaceuticals Inc | Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility |
US5726969A (en) * | 1994-12-28 | 1998-03-10 | Matsushita Electric Industrial Co., Ltd. | Optical recording medium having dual information surfaces |
EP1251502B1 (en) * | 1995-10-09 | 2004-07-28 | Matsushita Electric Industrial Co., Ltd. | An optical disk with an optical barcode |
CN100414612C (zh) * | 1995-10-09 | 2008-08-27 | 松下电器产业株式会社 | 光盘 |
DE69732728T2 (de) * | 1996-01-26 | 2006-04-06 | Sharp K.K. | Optisches Aufzeichnungsmedium und Optische Aufzeichnungs- Wiedergabevorrichtung und Verfahren zur Herstellung eines optischen Aufzeichnungsmediums |
US5883958A (en) * | 1996-04-01 | 1999-03-16 | Sony Corporation | Method and device for data decryption, a method and device for device identification, a recording medium, a method of disk production, and a method and apparatus for disk recording |
US5839443A (en) * | 1996-05-16 | 1998-11-24 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
JP2856390B2 (ja) * | 1996-07-26 | 1999-02-10 | 株式会社日立製作所 | 情報記録媒体及びそれを用いた記録再生方法 |
DE59712555D1 (de) * | 1996-06-05 | 2006-04-06 | Roche Diagnostics Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US5686511A (en) | 1996-06-28 | 1997-11-11 | The Valspar Corporation | Esterifying epoxy resin with carboxyl polymer and quenching |
DE69738507T2 (de) * | 1996-07-10 | 2008-06-12 | Hitachi, Ltd. | Verfahren und System zum Datenzugriff für einen optischen Plattenspieler |
ATE493998T1 (de) | 1996-08-08 | 2011-01-15 | Amylin Pharmaceuticals Inc | Pharmazeutische zusammensetzung mit einem exendin-4-peptid |
US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
CN1311457C (zh) * | 1996-12-19 | 2007-04-18 | 松下电器产业株式会社 | 光盘再生装置 |
AU739020B2 (en) | 1997-01-07 | 2001-10-04 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
US6051557A (en) * | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
JPH1131357A (ja) * | 1997-07-08 | 1999-02-02 | Pioneer Electron Corp | 情報データの記録方法 |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
NZ502592A (en) | 1997-08-08 | 2002-03-28 | Amylin Pharmaceuticals Inc | Exendin agonist peptides and their use in the treatment of type I and II diabetes |
JPH11196084A (ja) * | 1997-10-31 | 1999-07-21 | Matsushita Electric Ind Co Ltd | 暗号化システム |
BR9815670A (pt) | 1997-11-14 | 2000-10-17 | Amylin Pharmaceuticals Inc | Compostos agonistas de exendina |
DE69839021T3 (de) | 1997-11-14 | 2013-08-08 | Amylin Pharmaceuticals, Llc | Neuartige exendin agonisten |
WO1999040788A1 (en) | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
EP1140145B2 (en) | 1999-01-14 | 2019-05-15 | Amylin Pharmaceuticals, LLC | Novel exendin agonist formulations and methods of administration thereof |
DE60032331T2 (de) | 1999-01-14 | 2007-06-21 | Amylin Pharmaceuticals, Inc., San Diego | Exendine zur glucagon suppression |
US6451974B1 (en) * | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6519213B1 (en) * | 1999-06-29 | 2003-02-11 | Oak Technology, Inc. | Method and apparatus for reading data from a disk |
-
2000
- 2000-01-14 DE DE60032331T patent/DE60032331T2/de not_active Expired - Lifetime
- 2000-01-14 JP JP2000593169A patent/JP2002538084A/ja active Pending
- 2000-01-14 ES ES06002683T patent/ES2343072T3/es not_active Expired - Lifetime
- 2000-01-14 AT AT06002683T patent/ATE460942T1/de not_active IP Right Cessation
- 2000-01-14 ES ES00902415T patent/ES2278589T3/es not_active Expired - Lifetime
- 2000-01-14 DK DK00902415T patent/DK1143989T3/da active
- 2000-01-14 EP EP06002683A patent/EP1658856B1/en not_active Expired - Lifetime
- 2000-01-14 AU AU24136/00A patent/AU770712B2/en not_active Expired
- 2000-01-14 KR KR1020077009281A patent/KR20070051948A/ko not_active Application Discontinuation
- 2000-01-14 US US09/889,331 patent/US6872700B1/en not_active Expired - Lifetime
- 2000-01-14 CA CA002356331A patent/CA2356331C/en not_active Expired - Lifetime
- 2000-01-14 CN CNB008050171A patent/CN100425284C/zh not_active Expired - Lifetime
- 2000-01-14 DE DE60044041T patent/DE60044041D1/de not_active Expired - Lifetime
- 2000-01-14 NZ NZ512657A patent/NZ512657A/xx not_active IP Right Cessation
- 2000-01-14 PT PT00902415T patent/PT1143989E/pt unknown
- 2000-01-14 WO PCT/US2000/000942 patent/WO2000041548A2/en not_active Application Discontinuation
- 2000-01-14 KR KR1020017008892A patent/KR20020001719A/ko not_active Application Discontinuation
- 2000-01-14 BR BRPI0007823A patent/BRPI0007823A8/pt not_active Application Discontinuation
- 2000-01-14 EP EP00902415A patent/EP1143989B1/en not_active Expired - Lifetime
- 2000-01-14 AT AT00902415T patent/ATE347901T1/de active
-
2001
- 2001-07-12 NO NO20013469A patent/NO328077B1/no not_active IP Right Cessation
-
2002
- 2002-10-29 HK HK02107813.8A patent/HK1046105A1/zh unknown
-
2004
- 2004-05-26 AU AU2004202293A patent/AU2004202293B2/en not_active Expired
-
2005
- 2005-03-18 US US11/083,730 patent/US7153825B2/en not_active Expired - Lifetime
-
2006
- 2006-10-19 US US11/584,114 patent/US7407932B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 CY CY20071100286T patent/CY1106347T1/el unknown
-
2010
- 2010-05-11 NO NO2010010C patent/NO2010010I1/no not_active Application Discontinuation
- 2010-05-20 NO NO2010012C patent/NO2010012I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20013469L (no) | Fremgangsmåter for glukagonsuppresjon | |
NO20053224D0 (no) | Patient controlled drug administration device. | |
EE200300212A (et) | Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks | |
NO20011721D0 (no) | N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor | |
DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
ZA200405657B (en) | Formulation & dosage form for the controlled delivery of therapeutic agents. | |
NO20022334D0 (no) | Ny sammensetning og anvendelse | |
ATE289500T1 (de) | Ophtalmologische medikamentenzuführvorrichtung | |
HUP0400200A3 (en) | Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
AU2003220956A1 (en) | Insulin administration apparatus | |
AU2003293593A8 (en) | Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration | |
DE602004005564D1 (de) | Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten | |
NO20035602D0 (no) | Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer | |
IT1311921B1 (it) | Composti farmaceutici. | |
IL159576A0 (en) | Pharmaceutical formulation for the intramuscular administration of fulvestrant | |
ZA200309513B (en) | Novel heterocyclic derivatives and medicinal use thereof. | |
DK1494650T3 (da) | Farmaceutisk formulering, der indeholder melatonin | |
FR2820311B3 (fr) | Distributeur de medicament portatif | |
DE69934902D1 (de) | Medikament gegen drogenabhängigkeit | |
GB0212790D0 (en) | Medicament for the treatment of diabetes | |
ITUD20030196A1 (it) | Procedimento per la preparazione di dosaggi farmaceutici contenenti molteplici principi attivi. | |
RU2001109481A (ru) | Антиангинальное средство | |
SE0000332D0 (sv) | New use | |
IT1312082B1 (it) | Derivati morfinoidi, procedimento per la loro preparzione e loroimpiego terapeutico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: BYETTA; NAT. REG. NO/DATE: EU/1/06/362/001-004/NO 20061120; FIRST REG. NO/DATE: EU , EU/1/06/362/001-004 20061120 Spc suppl protection certif: 2010010 Filing date: 20100511 Free format text: PRODUCT NAME: BYETTA; NAT. REG. NO/DATE: EU/1/06/362/001-4/NO 20061120; FIRST REG. NO/DATE: EU/1/06/362/001-004 20061120 Spc suppl protection certif: 2010012 Filing date: 20100520 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ASTRAZENECA PHARMACEUTICALS LP, US |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ASTRAZENECA PHARMACEUTICALS LP, US |
|
MK1K | Patent expired |